Back to Search Start Over

Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis.

Authors :
Payancé, A.
Bissonnette, J.
Roux, O.
Elkrief, L.
Gault, N.
Francoz, C.
Nekachtali, O.
Soubrane, O.
Lebrec, D.
Valla, D.
Durand, F.
Rautou, P.‐E.
Source :
Alimentary Pharmacology & Therapeutics; May2016, Vol. 43 Issue 9, p966-973, 8p
Publication Year :
2016

Abstract

Background Beta-blockers may have to be interrupted in patients with cirrhosis. The concept of a rebound after interruption of beta-blockers is based on an animal study and on isolated case reports of variceal bleeding. Aim To determine if a rebound occurs in patients with cirrhosis following abrupt interruption of beta-blockers. Methods We prospectively included all consecutive patients with cirrhosis undergoing right heart and hepatic vein catheterisation. Four groups were defined: 'no beta-blockers' including patients not receiving beta-blockers; '≤1 day', '2-3 days' and '≥4 days' classified according to the time patients had interrupted beta-blockers before catheterisation. Results were expressed as median (interquartile range). Results A total of 150 patients were included. Among the 25 patients in the groups '2-3 days' and '≥4 days', median duration of beta-blockers interruption was 4 (3-6) days. No gastrointestinal bleeding occurred during that period, nor during the following month. Hepatic venous pressure gradient was not different among patients in usually treated with beta-blockers. After adjustment, beta-blockers interruption was not associated with hepatic venous pressure gradient. Cardiac index was higher in the '≥4 days' group [4.6 L/min/m<superscript>2</superscript> (3.5-5.1)] than in the '≤1 day' group [3.4 (2.6-4.0); P = 0.001] or in the '2-3 days' group [3.1 (2.7-3.7); P = 0.007], but not different from the 'no beta-blockers' group. Conclusions Abrupt interruption of beta-blockers is associated neither with an apparent increase in the risk of variceal bleeding nor with a haemodynamic rebound. Thus, interruption of beta-blockers in patients with cirrhosis may not require particular dosing or surveillance. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02692813
Volume :
43
Issue :
9
Database :
Complementary Index
Journal :
Alimentary Pharmacology & Therapeutics
Publication Type :
Academic Journal
Accession number :
114190572
Full Text :
https://doi.org/10.1111/apt.13577